. 2023 Jul 5;7(21):6790–6799. doi: 10.1182/bloodadvances.2023009961
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2.
Study treatment schedule and doses. DF, defibrotide.